Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug.
Their research, published today in the journal Molecular Pharmaceutics, shows how a new anti-heroin formulation that is safe in animal models remains stable at room temperature for at least 30 days. As a result, the vaccine is close to being ready for human testing.
“The heroin vaccine is one step closer to clinical evaluation,” says Candy S. Hwang, PhD, first author of the study and a research associate at TSRI.
According to the National Institute on Drug Abuse, 15,446 Americans died from heroin overdose between 2000 and 2016, and the mortality rates are increasing. Heroin abuse has been further fueled by a rise in prescription opioid abuse—studies show that opioid pain reliever users are 40 times more likely to abuse heroin.
The first formulation of the heroin vaccine was developed in 2013 by a team led by Kim D. Janda, PhD, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. It has been shown to be effective—and safe—in both mouse and non-human primate models.
The vaccine works by training the immune system antibodies to recognize and bind to heroin molecules, blocking the drug from reaching the brain to cause a “high.” Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use.
The heroin molecule does not naturally prompt an antibody response, so researchers attach it to a carrier protein that alerts the immune system to start making antibodies. Scientists also add an ingredient called an adjuvant to the vaccine, which boosts the immune response and makes the vaccine more effective.
Hwang says, “Our goal was to prepare a vaccine that could be advanced to clinical trials. As such, we were looking for the best combination of ‘hapten’ (the heroin molecule), carrier protein and adjuvant to keep the vaccine both stable for transport and storage but still efficacious.”
For the new study, the researchers investigated how 20 different carrier protein/adjuvant combinations worked, including shelf stability based on temperature and storage time and whether the formulation was a liquid or powder.
Their experiments in rodent models showed that the best vaccine formulation contained a carrier protein called tetanus toxoid (TT) and adjuvants called alum and CpG ODN. The discovery that alum worked best as an adjuvant was especially significant since alum is one of the few adjuvants used in vaccines already approved by the U.S. Food and Drug Administration. The researchers also found that there was no difference in how well it worked between the liquid and powder versions of this formulation.
Hwang notes that the best vaccine formulation showed protection against lethal doses of heroin. This is particularly important as many heroin addicts have succumb to overdose and death during their attempts to quit the drug.
With this new study, the researchers have shown that the vaccine is safe and effective in animal models, stable under clinical conditions and reliant on an already-approved adjuvant. The next step is to find a producer to make the vaccine on a large scale.
“We believe that a heroin vaccine would be tremendously beneficial for people who have a heroin substance use disorder but have found difficulty in trying to quit,” says Hwang.
Learn more: Heroin vaccine blocks lethal overdose
The Latest on: Heroin vaccine
- Stepping Closer to Develop Vaccine or Drug for Late-onset Alzheimer's on December 18, 2018 at 4:06 am
Novel potential therapeutic approach brings scientists a step closer in developing a vaccine or drug to prevent late-onset Alzheimer's disease, reports a new study. The findings of the study are publi... […]
- Vaccine or drug for late-onset Alzheimer's could be on the way on December 18, 2018 at 3:18 am
PanARMENIAN.Net - UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer's disease, opening the door to development of a drug that cou... […]
- Research opens door to development of drug or vaccine for late-onset Alzheimer's on December 17, 2018 at 9:11 am
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer's disease, opening the door to development of a drug that could be administered ... […]
- Research suggests path to vaccine or drug for late-onset Alzheimer's on December 17, 2018 at 7:22 am
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer's disease, opening the door to development of a drug that could be ... […]
- Path to vaccine or drug for late-onset Alzheimer's on December 17, 2018 at 5:18 am
Researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer's disease, opening the door to development of a drug that could be administered before age ... […]
- Scientists Test Vaccine to Combat Opioid Addiction on December 13, 2018 at 1:09 pm
Researchers at The Scripps Research Institute say they have created a vaccine with opioid antibodies that can work against several synthetic opioids and could help treat people’s addiction by blocking ... […]
- HealthWatch: TB Vaccine: Wonder Drug for Diabetes and More? on December 13, 2018 at 9:36 am
Orlando, Fla. (Ivanhoe Newswire) - Tuberculosis is the worlds' leading infectious cause of death. BCG is a vaccine given to infants and children in countries where TB is common. Now recent reports are ... […]
- Cancer Vaccines: Analytical Tool 2018: 372 Companies Plus Partners, Developing 767 Cancer Vaccine Drugs on December 13, 2018 at 8:12 am
This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your cancer vaccine drug surveillance and intelligence, allowing you to power your decision ... […]
- GHIT Fund Announces New Investments in Vaccines for Dengue and Leishmaniasis, and Drug Screening for Malaria and Tuberculosis on December 12, 2018 at 5:08 pm
TOKYO, Dec. 12, 2018 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of 520 million yen (US$4.6 million*) to support four partnerships to develop new lifesa... […]
- Drug firm can’t keep up with demand for shingles vaccine on December 8, 2018 at 4:04 pm
A national shortage of a new vaccine to protect against the painful rash known as shingles is worsening, say pharmacists and consumers, even as the manufacturer announced plans last week for more cons... […]
via Google News and Bing News